Delivery Order SPE2DR25D1205-SPE2DR26F0WH3
- Not listed
- The Defense Logistics Agency awarded a $1,510.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL pharmaceutical supplies on September 3, 2025, with completion targeted for September 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $35,031.32 to AmerisourceBergen Drug Corp for HUMIRA Pen 40mg/4ml pharmaceutical supplies on November 3, 2025, with completion by November 4, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a competitive procurement under the company's broader pharmaceutical supply contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product for treating autoimmune conditions. This competitively awarded, firm fixed-price delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,812.52 to AmerisourceBergen Drug Corp for HUMIRA (Pen) 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside award executed under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. The place of...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a $4,775.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, with an ultimate completion date of November 4, 2025. This non-set-aside competitive award was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle valued through December 2026. The...
- The Defense Logistics Agency awarded a $17,422.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in treating inflammatory conditions. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 4, 2025, and performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $4,531.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable pharmaceutical product used in treating autoimmune conditions. The award, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency awarded a $3,183.92 delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of various inflammatory conditions. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0WH3Delivery Order
The Defense Logistics Agency awarded a $54.78K firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Pen) 40 mg/0.4 mL on November 5, 2025, with an ultimate completion date of November 6, 2025. This non-set-aside award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The product being delivered is a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis, psoriasis, and other autoimmune conditions, indicating this procurement supports military healthcare system requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical federal medical procurement vendor for the Defense Logistics Agency and the Defense Health Agency. The company's extensive federal contract portfolio demonstrates consistent competitive success across multiple therapeutic domains, including specialty medications, biologics, and vaccines. This delivery order exemplifies the company's ongoing role in supplying pharmaceutical products to support military medical operations and veteran healthcare systems through the DLA's comprehensive pharmaceutical prime vendor framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.8k | 11/5/25 |